HRP20191794T1 - Deoksinukleozidna terapija bolesti uzrokovanih neuravnoteženim nukleotidnim fondovima, uključujući sindrome gubitka mitohondrijske dna - Google Patents

Deoksinukleozidna terapija bolesti uzrokovanih neuravnoteženim nukleotidnim fondovima, uključujući sindrome gubitka mitohondrijske dna Download PDF

Info

Publication number
HRP20191794T1
HRP20191794T1 HRP20191794TT HRP20191794T HRP20191794T1 HR P20191794 T1 HRP20191794 T1 HR P20191794T1 HR P20191794T T HRP20191794T T HR P20191794TT HR P20191794 T HRP20191794 T HR P20191794T HR P20191794 T1 HRP20191794 T1 HR P20191794T1
Authority
HR
Croatia
Prior art keywords
preparation
per day
accordance
intended
effective amount
Prior art date
Application number
HRP20191794TT
Other languages
English (en)
Croatian (hr)
Inventor
Michio Hirano
Caterina Garone
Ramon MARTI
Original Assignee
The Trustees Of Columbia University In The City Of New York
Fundació Hospital Universitari Vall D'hebron - Institut De Recerca
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of Columbia University In The City Of New York, Fundació Hospital Universitari Vall D'hebron - Institut De Recerca filed Critical The Trustees Of Columbia University In The City Of New York
Publication of HRP20191794T1 publication Critical patent/HRP20191794T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
HRP20191794TT 2015-06-17 2016-06-17 Deoksinukleozidna terapija bolesti uzrokovanih neuravnoteženim nukleotidnim fondovima, uključujući sindrome gubitka mitohondrijske dna HRP20191794T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562180914P 2015-06-17 2015-06-17
PCT/US2016/038110 WO2016205671A1 (en) 2015-06-17 2016-06-17 Deoxynucleoside therapy for diseases caused by unbalanced nucleotide pools including mitochondrial dna depletion syndromes
EP16812537.5A EP3310362B1 (en) 2015-06-17 2016-06-17 Deoxynucleoside therapy for diseases caused by unbalanced nucleotide pools including mitochondrial dna depletion syndromes

Publications (1)

Publication Number Publication Date
HRP20191794T1 true HRP20191794T1 (hr) 2020-02-07

Family

ID=57546446

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20191794TT HRP20191794T1 (hr) 2015-06-17 2016-06-17 Deoksinukleozidna terapija bolesti uzrokovanih neuravnoteženim nukleotidnim fondovima, uključujući sindrome gubitka mitohondrijske dna
HRP20200949TT HRP20200949T1 (hr) 2015-06-17 2020-06-15 Deoksinukleozidna terapija bolesti uzrokovanih neurevnoteženim fondovima nukleotida, uključujući sindrome manjka mitohondrijske dna

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20200949TT HRP20200949T1 (hr) 2015-06-17 2020-06-15 Deoksinukleozidna terapija bolesti uzrokovanih neurevnoteženim fondovima nukleotida, uključujući sindrome manjka mitohondrijske dna

Country Status (24)

Country Link
US (5) US10471087B2 (enExample)
EP (3) EP3505174B1 (enExample)
JP (3) JP6599484B2 (enExample)
KR (3) KR20180039624A (enExample)
CN (2) CN116726035A (enExample)
AU (3) AU2016280293B2 (enExample)
BR (2) BR122020021913B1 (enExample)
CA (1) CA2989653A1 (enExample)
CY (2) CY1122605T1 (enExample)
DK (2) DK3310362T3 (enExample)
ES (2) ES2748556T3 (enExample)
HK (1) HK1252133A1 (enExample)
HR (2) HRP20191794T1 (enExample)
HU (2) HUE046399T2 (enExample)
IL (3) IL275256B2 (enExample)
LT (2) LT3505174T (enExample)
MX (2) MX2017016425A (enExample)
PL (2) PL3310362T3 (enExample)
PT (2) PT3505174T (enExample)
RS (2) RS60572B1 (enExample)
RU (1) RU2721492C2 (enExample)
SI (2) SI3310362T1 (enExample)
SM (2) SMT202000399T1 (enExample)
WO (1) WO2016205671A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
US10292996B2 (en) * 2015-03-26 2019-05-21 The Trustees Of Columbia University In The City Of New York Deoxyribonucleoside monophospate bypass therapy for mitochondrial DNA depletion syndrome
US10471087B2 (en) * 2015-06-17 2019-11-12 The Trustees Of Columbia University In The City Of New York Deoxynucleoside therapy for diseases caused by unbalanced nucleotide pools including mitochondrial DNA depletion syndromes
EP3393470B1 (en) 2015-12-22 2021-01-20 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
CA3007286A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Fenfluramine compositions and methods of preparing the same
MX2019001799A (es) 2016-08-24 2019-06-13 Zogenix International Ltd Formulacion para inhibir la formacion de agonistas de 5-ht2b y metodos de utilizacion de la misma.
WO2019051097A1 (en) 2017-09-08 2019-03-14 The Regents Of The University Of California RNA-GUIDED ENDONUCLEASE FUSION POLYPEPTIDES AND METHODS OF USING SAME
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
WO2019200340A1 (en) 2018-04-12 2019-10-17 Modis Therapeutics Inc. Prodrugs of deoxynucleosides for treatment of diseases cased by unbalanced nucleotide pools
MX2020010994A (es) 2018-04-18 2021-01-08 Univ Columbia Terapia de gen para enfermedades causadas por combinaciones desequilibradas de nucleótidos que incluyen síndromes de agotamiento de adn mitocondrial.
WO2019216919A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
EA202191079A1 (ru) 2018-11-19 2021-09-20 Зодженикс Интернэшнл Лимитед Способы лечения синдрома ретта с применением фенфлурамина
EP4017502A4 (en) * 2019-08-19 2023-11-01 Modis Therapeutics Inc. POLYMORPH FORMS OF DEOXYCYTIDINE, COMPOSITIONS COMPRISING THEM AND USES
CN114340641B (zh) * 2019-09-05 2025-04-04 米托瑞因博治疗股份有限公司 治疗线粒体dna缺失障碍
WO2021188840A1 (en) * 2020-03-19 2021-09-23 Rewrite Therapeutics, Inc. Methods and compositions for directed genome editing
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US20220096514A1 (en) * 2020-09-29 2022-03-31 Zogenix International Limited Methods of treating thymidine kinase 2 deficiency by administering deoxycytidine and deoxythymidine
WO2022145439A1 (ja) * 2020-12-28 2022-07-07 ヤマサ醤油株式会社 筋萎縮抑制剤及び筋萎縮を抑制させる方法
CN117120060A (zh) * 2021-03-26 2023-11-24 周格尼克斯-莫迪斯公司 含有嘌呤和嘧啶的水溶液及其用途
EP4355336A4 (en) * 2021-06-18 2025-05-07 UCB Biosciences, Inc. DEOXYNUCLEOSIDE PRODRUGS FOR THE TREATMENT OF MITOCHONDRIAL DISEASES CAUSED BY UNBALANCED NUCLEOTIDE GROUPS
EP4554596A1 (en) * 2022-07-12 2025-05-21 UCB Biosciences, Inc. Methods for increasing the bioavailability of nucleoside medicinal agents
WO2024206595A2 (en) * 2023-03-30 2024-10-03 The Trustees Of Columbia University In The City Of New York Pharmacological therapy for mitochondrial dna depletion deletions syndrome involving mutations in the guk1 gene

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1911237B (zh) * 1998-08-10 2010-09-15 艾丹尼克斯(开曼)有限公司 用于治疗乙型肝炎的β-L-2＇-脱氧-核苷
KR100879559B1 (ko) * 1999-02-23 2009-01-22 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 미토콘드리아 장애의 치료 또는 예방용 제약조성물
US6596700B2 (en) * 2000-05-26 2003-07-22 Idenix Pharmaceuticals Inc. Methods of treating hepatitis delta virus infection with β-L-2'-deoxy-nucleosides
WO2012125848A2 (en) * 2011-03-16 2012-09-20 Baylor College Of Medicine A method for comprehensive sequence analysis using deep sequencing technology
US10292996B2 (en) 2015-03-26 2019-05-21 The Trustees Of Columbia University In The City Of New York Deoxyribonucleoside monophospate bypass therapy for mitochondrial DNA depletion syndrome
PL3302499T3 (pl) * 2015-06-05 2023-07-24 Fundació Hospital Universitari Vall D'hebron - Institut De Recerca Leczenie chorób mitochondrialnych
US10471087B2 (en) * 2015-06-17 2019-11-12 The Trustees Of Columbia University In The City Of New York Deoxynucleoside therapy for diseases caused by unbalanced nucleotide pools including mitochondrial DNA depletion syndromes

Also Published As

Publication number Publication date
BR122020021913B1 (pt) 2021-07-06
LT3310362T (lt) 2019-11-11
KR20250048602A (ko) 2025-04-09
PT3310362T (pt) 2019-10-29
CY1123107T1 (el) 2021-10-29
RS59724B1 (sr) 2020-01-31
PT3505174T (pt) 2020-07-06
US20210244754A1 (en) 2021-08-12
JP6599484B2 (ja) 2019-10-30
RU2018101305A3 (enExample) 2019-10-31
IL275256A (en) 2020-07-30
CN107847512A (zh) 2018-03-27
KR20180039624A (ko) 2018-04-18
HK1252133A1 (zh) 2019-05-17
DK3310362T3 (da) 2019-10-07
SI3505174T1 (sl) 2021-02-26
KR20220018623A (ko) 2022-02-15
AU2021250841A1 (en) 2021-11-04
US11666592B2 (en) 2023-06-06
AU2020204042B2 (en) 2021-07-15
MX389016B (es) 2025-03-20
CN116726035A (zh) 2023-09-12
CY1122605T1 (el) 2021-03-12
IL256331B (en) 2020-08-31
JP6675037B2 (ja) 2020-04-01
WO2016205671A9 (en) 2018-01-04
EP3310362B1 (en) 2019-08-28
ES2808148T3 (es) 2021-02-25
EP3569236A1 (en) 2019-11-20
AU2016280293B2 (en) 2020-07-02
WO2016205671A1 (en) 2016-12-22
HRP20200949T1 (hr) 2020-10-02
RS60572B1 (sr) 2020-08-31
IL275255A (en) 2020-07-30
AU2021250841B2 (en) 2023-02-09
IL275255B (en) 2021-04-29
AU2016280293A1 (en) 2018-02-08
EP3505174A1 (en) 2019-07-03
DK3505174T3 (da) 2020-07-13
US20230277577A1 (en) 2023-09-07
CA2989653A1 (en) 2016-12-22
SI3310362T1 (sl) 2020-02-28
RU2018101305A (ru) 2019-07-17
US11110111B2 (en) 2021-09-07
IL275256B2 (en) 2023-09-01
EP3505174B1 (en) 2020-04-29
SMT202000399T1 (it) 2020-09-10
US12251392B2 (en) 2025-03-18
JP2020019791A (ja) 2020-02-06
US20250360154A1 (en) 2025-11-27
IL256331A (en) 2018-02-28
PL3310362T3 (pl) 2020-04-30
ES2748556T3 (es) 2020-03-17
HUE050678T2 (hu) 2020-12-28
HUE046399T2 (hu) 2020-03-30
EP3310362A1 (en) 2018-04-25
SMT201900571T1 (it) 2019-11-13
AU2020204042A1 (en) 2020-07-09
PL3505174T3 (pl) 2020-08-24
US20180133241A1 (en) 2018-05-17
JP2020019792A (ja) 2020-02-06
JP2018521993A (ja) 2018-08-09
MX2017016425A (es) 2018-12-11
MX2020000269A (es) 2022-01-03
US20200038424A1 (en) 2020-02-06
US10471087B2 (en) 2019-11-12
RU2721492C2 (ru) 2020-05-19
RU2020112901A (ru) 2020-06-05
LT3505174T (lt) 2020-09-10
EP3310362A4 (en) 2018-12-19
IL275256B1 (en) 2023-05-01
JP7036782B2 (ja) 2022-03-15
BR112017027079B1 (pt) 2021-04-27

Similar Documents

Publication Publication Date Title
HRP20191794T1 (hr) Deoksinukleozidna terapija bolesti uzrokovanih neuravnoteženim nukleotidnim fondovima, uključujući sindrome gubitka mitohondrijske dna
JP2018521993A5 (enExample)
FI3377534T3 (fi) Keuhkosyövän hoito käyttäen anti-pd-1-vasta-aineen ja anti-ctla-4-vasta-aineen yhdistelmää
JP2017036288A5 (enExample)
JP2015078220A5 (enExample)
HK1252759A1 (zh) 肽寡核苷酸缀合物
IL295418B1 (en) Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus
RU2015120263A (ru) Содержащие неврологический компонент питательные композиции и их применение
MY198880A (en) Phosphoramidate nucleoside derivatives as anticancer agents
JP2006504745A5 (enExample)
MX2015009006A (es) Oligonucleotidos inhibitorios y su uso en terapia.
MX2019012051A (es) Proteinas para el tratamiento de trastornos de la funcion de la barrera epitelial.
HRP20192184T1 (hr) Optimizirana visokodozna tableta mesalazina
JP2017512194A5 (enExample)
JP2017507142A5 (enExample)
HRP20192246T1 (hr) Marker za poremećaje kisele sfingomijelinaze i njegova uporaba
WO2016040814A3 (en) Disulfide polymers and methods of use
JP2016014051A5 (enExample)
HRP20240543T1 (hr) Pripravak za liječenje upalnih bolesti crijeva
HRP20191322T1 (hr) Antitumorska kombinacija koja sadži kabazitaksel i cisplatin
WO2014186388A3 (en) Administration of nedd8-activating enzyme inhibitor and chemotherapeutic agents
Yadav et al. Effectiveness of core muscle stabilization training on dynamic balance in mechanical low back pain patients
CN206228526U (zh) 一种用于促进卧床患者肢体功能恢复的多功能病床
JP2014162761A5 (enExample)
Yakovenko Social responsibility of state regulation measures in relation to agriculture in Ukraine in the context of the COVID-19 pandemic